Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod for Acute NMOSD Attack
NCT06497374Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Jul 2024
- Primary completion
- Dec 2025
- Modality
- Antibody Fragments
01
Overview
A Phase 2 trial of efgartigimod alfa in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Tianjin Medical University General Hospital. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
efgartigimod alfa
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT06497374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06497374.